These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 38835784)

  • 21. Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments.
    Taylor DD; Gercel-Taylor C
    Semin Immunopathol; 2011 Sep; 33(5):441-54. PubMed ID: 21688197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor-Derived Exosomes and Their Role in Cancer Progression.
    Whiteside TL
    Adv Clin Chem; 2016; 74():103-41. PubMed ID: 27117662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy.
    Nam GH; Choi Y; Kim GB; Kim S; Kim SA; Kim IS
    Adv Mater; 2020 Dec; 32(51):e2002440. PubMed ID: 33015883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models.
    Lu Z; Zuo B; Jing R; Gao X; Rao Q; Liu Z; Qi H; Guo H; Yin H
    J Hepatol; 2017 Oct; 67(4):739-748. PubMed ID: 28549917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review.
    Ye Y; Xu C; Chen F; Liu Q; Cheng N
    Front Immunol; 2021; 12():771201. PubMed ID: 34899721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exosomes: A potential tool for immunotherapy of ovarian cancer.
    Gong X; Chi H; Strohmer DF; Teichmann AT; Xia Z; Wang Q
    Front Immunol; 2022; 13():1089410. PubMed ID: 36741380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Engineering exosomes to reshape the immune microenvironment in breast cancer: Molecular insights and therapeutic opportunities.
    Cao J; Lv G; Wei F
    Clin Transl Med; 2024 Apr; 14(4):e1645. PubMed ID: 38572668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer.
    Qiu P; Guo Q; Yao Q; Chen J; Lin J
    Front Immunol; 2021; 12():736030. PubMed ID: 34659224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Roles of the Exosomes Derived From Myeloid-Derived Suppressor Cells in Tumor Immunity and Cancer Progression.
    Chen Z; Yuan R; Hu S; Yuan W; Sun Z
    Front Immunol; 2022; 13():817942. PubMed ID: 35154134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenges and opportunities for cancer stem cell-targeted immunotherapies include immune checkpoint inhibitor, cancer stem cell-dendritic cell vaccine, chimeric antigen receptor immune cells, and modified exosomes.
    Alqarni A; Jasim SA; Altalbawy FMA; Kaur H; Kaur I; Rodriguez-Benites C; Deorari M; Alwaily ER; Al-Ani AM; Redhee AH
    J Biochem Mol Toxicol; 2024 Jun; 38(6):e23719. PubMed ID: 38764138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Roles of exosomes in cancer chemotherapy resistance, progression, metastasis and immunity, and their clinical applications (Review).
    Wang X; Zhou Y; Ding K
    Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34013358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunology and breast cancer: toward a new way of understanding breast cancer and developing novel therapeutic strategies.
    Gingras I; Azim HA; Ignatiadis M; Sotiriou C
    Clin Adv Hematol Oncol; 2015 Jun; 13(6):372-82. PubMed ID: 26352893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exosomes-based immunotherapy for cancer: Effective components in the naïve and engineered forms.
    Bao H; Chen Y; Zhang Y; Lan H; Jin K
    Int Immunopharmacol; 2024 Sep; 139():112656. PubMed ID: 39043104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent Advances in Experimental Models of Breast Cancer Exosome Secretion, Characterization and Function.
    Pelissier Vatter FA; Lucotti S; Zhang H
    J Mammary Gland Biol Neoplasia; 2020 Dec; 25(4):305-317. PubMed ID: 33351162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential.
    Pi YN; Qi WC; Xia BR; Lou G; Jin WL
    Front Immunol; 2021; 12():697083. PubMed ID: 34295338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of Tumor Markers for Breast Cancer Immunotherapy.
    Fang Q; Shen G; Xie Q; Guan Y; Liu X; Ren D; Zhao F; Liu Z; Ma F; Zhao J
    Curr Mol Med; 2024; 24(5):547-564. PubMed ID: 37157196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Personalized medicine and back-allogeneic exosomes for cancer immunotherapy.
    Samuel M; Gabrielsson S
    J Intern Med; 2021 Feb; 289(2):138-146. PubMed ID: 31359504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Harnessing the immune system for the treatment of breast cancer.
    Jiang X
    J Zhejiang Univ Sci B; 2014 Jan; 15(1):1-15. PubMed ID: 24390741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Role of Exosomes in Breast Cancer.
    Lowry MC; Gallagher WM; O'Driscoll L
    Clin Chem; 2015 Dec; 61(12):1457-65. PubMed ID: 26467503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The rising roles of exosomes in the tumor microenvironment reprogramming and cancer immunotherapy.
    Wu Y; Han W; Dong H; Liu X; Su X
    MedComm (2020); 2024 Apr; 5(4):e541. PubMed ID: 38585234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.